Back to top
more

Surface Oncology, Inc. (SURF)

(Delayed Data from NSDQ)

$4.87 USD

4.87
37,567

+0.02 (0.41%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[SURF]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Industry: Medical - Products

Record: 1

09/08/2023

Company Report

Pages: 4

Dropping Coverage of SURF Following Acquisition by CHRS

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 2

08/02/2023

Company Report

Pages: 5

Q2 Financials; CHRS Merger on Track for Sep 2023

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 3

06/20/2023

Company Report

Pages: 7

Surface to Be Acquired by Coherus; Downgrade to Neutral With a $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 4

06/16/2023

Company Report

Pages: 7

SURF to be Acquired by CHRS; Downgrading to NEUTRAL; PT to $1.15

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 5

05/05/2023

Company Report

Pages: 7

SRF388 Phase 2 Readouts Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 6

05/04/2023

Company Report

Pages: 7

1Q23 Financials; SRF388 Clinical Updates on Track for 2Q23

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 7

03/10/2023

Company Report

Pages: 7

Eyes on SRF388 Update in NSCLC; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 8

03/10/2023

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 9

03/09/2023

Company Report

Pages: 7

Q4/FY22 Financials; SRF388 (IL-27 mAb) data updates anticipated 1H23

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 10

11/03/2022

Daily Note

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 11

11/03/2022

Company Report

Pages: 8

SRF388 Moves Forward in NSCLC; SRF617 Development Shelved; Lower PT to $6.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 12

11/02/2022

Company Report

Pages: 7

Q3 Financials; Monotherapy SRF388 Responses in sqNSCLC; SRF617 Paused

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 13

08/08/2022

Company Report

Pages: 7

Development Programs Progressing; SRF617 Clinical Update Expected in 2H22; Lower $8.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 14

08/04/2022

Daily Note

Pages: 13

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 15

08/04/2022

Company Report

Pages: 6

Q2 Financials; SRF617 Data Update Later in 2022, SRF388 HCC Update in 1H:23

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 16

05/31/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 17

05/29/2022

Industry Report

Pages: 17

2022 Abstract Roundup For Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Products

Record: 18

05/11/2022

Company Report

Pages: 7

Q1 Financials; ASCO Update Ahead for SRF388

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 19

05/10/2022

Company Report

Pages: 6

Data Readouts on the Horizon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Products

Record: 20

03/03/2022

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party
// eof